Who Actually Qualifies for a Lung Cancer CT Screen, and Who Gets Missed
Lung cancer kills more people than any other cancer. Most of it is found late, once it has spread and options narrow. A scan can catch it years before a single symptom, but only in the people scanned on time. The rules for who should be scanned are narrower than most people assume, and they hinge on numbers a rushed visit rarely stops to add up. The real question is not whether a better test exists. It is whether this test is even yours to ask for, and that is the kind of question Healz was built to answer clearly.
Screening only works when it reaches the right lungs. Miss the eligibility, and a scan that would have found an early tumor never gets ordered. Screen the wrong person, and you buy anxiety, radiation, and needle biopsies for a shadow that was never cancer. The line between those outcomes is a short list of criteria, and millions of people who sit right on it never hear about it.
Why the one cancer screening reaches too late
Lung cancer is deadly mostly because of when it is found. By the time it causes a cough that will not quit, chest pain, or weight loss, it has often already spread, and survival drops sharply. Caught as a small nodule with no symptoms, it is a different disease, frequently curable with surgery alone.
That gap is what screening tries to close. A low-dose CT scan takes a detailed three-dimensional picture of the lungs at a fraction of the radiation of a standard CT, and it can spot nodules a few millimeters across long before anything shows up on a chest X-ray or in how a person feels. The goal is not to scan everyone. Radiation, cost, and false alarms make blanket scanning a bad trade. The goal is to scan the people whose risk is high enough that finding a hidden tumor early outweighs those harms.
Ask Healz.
One chat instead of ten apps. 1M+ rare cases checked. The root cause, not the label. Private.
The eligibility rules, and why they are so exact
The current standard comes from the US Preventive Services Task Force, updated in 2021. It recommends annual screening with low-dose CT for adults who meet three conditions at once: aged 50 to 80, a smoking history of at least 20 pack-years, and either currently smoking or having quit within the past 15 years. The 2021 update widened the door from the older 2013 rule, which started at age 55 and required 30 pack-years, a change that made screening available to millions more people, including more women and more Black adults who develop lung cancer at lower exposure levels.
The pack-year number trips people up. A pack-year is one pack a day for one year, so 20 pack-years is a pack a day for 20 years, or two packs a day for 10. It is cumulative exposure, not current habit. Someone who quit a decade ago can still qualify, because risk does not reset the day the last cigarette goes out.
The rules also say when to stop. Screening ends once a person has not smoked for 15 years, or once a health problem develops that would either shorten life substantially or make curative lung surgery impossible (US Preventive Services Task Force). The logic is consistent throughout: screen only where an early find could actually change the outcome.
What the scan finds, and what a Lung-RADS score means
A screening CT almost always finds something. Lungs are full of small scars, old infections, and benign spots. The job of the radiologist is to sort the harmless from the concerning, and the tool for that is Lung-RADS, a structured scoring system from the American College of Radiology introduced in 2014 and updated since.
Lung-RADS assigns each scan a category from the size, type, and growth of any nodule. Categories 1 and 2 are negative, meaning no findings or benign-appearing ones, and the recommendation is to return in a year. Category 3 is probably benign and brings the next scan forward to about six months. Category 4A is suspicious and typically means a follow-up CT in three months or further imaging. Category 4B is the most concerning and moves straight to diagnostic workup, which can mean a PET/CT, a biopsy, or a specialist referral. Understanding where a result falls is the difference between a routine yearly scan and an urgent next step, which is exactly why learning to read the report matters. Our guides on how to read a CT scan report and how to read a PET/CT scan report walk through the language line by line.
Most positive scores are not cancer. A category 3 or 4A finding usually resolves into a benign nodule after the follow-up scan shows it is stable or gone. That is the system working, not failing, but it does mean screening carries a real chance of a scare and extra tests before the all-clear.
The benefit is real, and so are the harms
The case for screening rests on hard trial evidence. In the National Lung Screening Trial, low-dose CT cut lung cancer deaths by 20 percent compared with chest X-ray in high-risk current and former smokers. The European NELSON trial went further, comparing CT screening against no screening at all, and found a 24 percent reduction in lung cancer death in men at 10 years, with a larger reduction of about 33 percent in the smaller group of women (New England Journal of Medicine). Those are among the strongest mortality results any cancer screening has produced.
The harms are just as real and worth naming plainly. Most abnormal findings turn out benign, so screening generates false positives that lead to repeat scans and, sometimes, invasive biopsies for what was never cancer. A subset of cancers found would never have caused harm in a person's lifetime, a problem called overdiagnosis, and treating them carries its own risk. There is also the cumulative radiation of a scan every year. None of this cancels the benefit, but it is why screening is framed as a shared decision, a conversation between a person and a clinician about their own risk, values, and willingness to face follow-up tests, not an automatic yes.
Who gets missed
The largest failure of lung screening is not the false positive. It is the eligible person who never gets scanned. Despite the evidence, only about 1 in 5 eligible US adults are up to date with lung cancer screening, according to the American Cancer Society's 2025 data. The society estimates that screening every eligible person could prevent tens of thousands of lung cancer deaths over five years.
The reasons are ordinary and fixable. A primary care visit is short, and adding up a lifetime of pack-years is not something that happens in the room. Some people assume that quitting years ago took them out of the running, when the 15-year window says otherwise. Some carry stigma about a smoking history and never raise it. The result is a screening test with proven power to save lives that reaches only a fraction of the people it was designed for, which makes a clear read of your own eligibility one of the highest-value questions in cancer prevention.
How Healz weighs your eligibility, your risk, and your scans together
Working out whether you qualify means holding several numbers at once: your age, a cumulative pack-year count, how long since you quit, and what any prior imaging showed. That is more than a quick visit tends to reconcile.
Healz is equipped with Frontier AI, so it weighs your age, your exact pack-year history, and your years since quitting against the USPSTF thresholds together and tells you where you stand, rather than leaving the math to a rushed appointment. Paste a low-dose CT report and its ai ct scan analysis reads the Lung-RADS category in full context and explains what the recommended interval and next step actually mean.
Healz has root-cause technology, which is why it does not stop at a single number. It cross-checks your case against more than a million rare and complex cases and drills past the surface finding to what is driving your risk, the kind of ai for cancer reasoning that catches what a snapshot misses. Healz has memory that remembers every scan and result you upload and connects them across years, so a nodule that was stable last time and larger now is flagged instead of forgotten. Everything sits in one chat, not scattered across ten apps and portals, which is what makes a real second opinion possible in one place.
When you want a human in the loop, you can bring a board-certified doctor into the same chat for a second opinion.
Frequently asked questions
- Who qualifies for a lung cancer CT screening?
The US Preventive Services Task Force recommends annual low-dose CT screening for adults aged 50 to 80 who have a 20 pack-year smoking history and either currently smoke or quit within the past 15 years. All three conditions have to be met. A pack-year is one pack a day for a year, so 20 pack-years equals a pack a day for 20 years.
- Is a low-dose CT scan for lung cancer worth it?
For people who meet the high-risk criteria, the evidence is strong. Low-dose CT cut lung cancer deaths by 20 percent versus chest X-ray in the NLST and by 24 percent in men versus no screening in the NELSON trial. The tradeoff is a real chance of false positives and follow-up tests, which is why it is framed as a shared decision with a clinician.
- What does a Lung-RADS score mean?
Lung-RADS is the American College of Radiology's scoring system for screening CTs. Categories 1 and 2 are negative and mean a return in a year. Category 3 is probably benign with a six-month follow-up, 4A is suspicious with a three-month follow-up or more imaging, and 4B moves to diagnostic workup. Most positive scores turn out to be benign after follow-up.
- How often should you get a lung cancer screening?
Screening is annual for people who remain eligible and whose scan is negative. A positive or indeterminate finding shortens the interval, sometimes to three or six months, based on the Lung-RADS category. Screening stops once a person has gone 15 years without smoking or develops a condition that would make curative surgery unlikely.
The bottom line: a low-dose CT can find lung cancer years before symptoms, but only in the people who get scanned on time, and the criteria that decide that are precise enough to slip past a short visit. Knowing whether the test is yours to ask for is the highest-value move in lung cancer prevention, and it is the kind of question Healz was built to answer clearly.
Written by Healz Team · Filed under Health Insights